Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer Tomoya YokotaSatoshi HamauchiKunihiro Fushiki Research 29 May 2024
Effect of PAWI-2 on pancreatic cancer stem cell tumors John R. CashmanEmily A. Cashman Research 25 May 2024
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants Michael J. HanleySteven ZhangNeeraj Gupta Research Open access 24 May 2024
Evolving or immutable - phase I solid tumor trials in the era of precision oncology Shannon S. StocktonG. Dan AyersJordan Berlin Research Open access 22 May 2024
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial Andrew J. ArmstrongRavit GevaJudy S. Wang Correction Open access 20 May 2024
In vitro results with minimal blood toxicity of a combretastatin A4 analogue Camila ChagasJaqueline Vital MansanoFernando Luiz Affonso Fonseca Research 17 May 2024
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer Xinyi LiuZihan GuoDegan Lu Research Open access 03 May 2024
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance Wenjie LiWei Wang Brief Report 03 May 2024
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia Huifen ZhouXiaoxia WuMiao Miao Research Open access 25 April 2024
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects Bei CaoTingting MaJuan Li Research 11 April 2024
The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells Fatemeh SafariSetareh BararpourFatemeh Omidi Chomachaei Research 27 March 2024
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer Tomoki HoriKazuhiro YamamotoIkuko Yano Research Open access 27 March 2024
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer Noboru YamamotoMiyako SatouchiMakoto Nishio Research Open access 26 March 2024
Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients Kazuma FujitaDaiki TaguchiMasatomo Miura Research Open access 22 March 2024
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors Maxime Chénard-PoirierAaron R. HansenManish R. Sharma Research Open access 14 March 2024
Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status Aaron ShaykevichDanbee ChaeRadhashree Maitra Research Open access 06 March 2024 Pages: 229 - 239
A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer Andrew H. KoAndrew L. CovelerShih-Yao Lin Research 05 March 2024 Pages: 221 - 228
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages Petra HenningAnna WesterlundUlf H. Lerner Research Open access 01 March 2024 Pages: 207 - 220
First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab? Yuanyuan ZhaoTing MeiYouling Gong Research Open access 22 February 2024 Pages: 196 - 206
Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma Xinxiu LiHongmeng SuHong Fan Research 19 February 2024 Pages: 185 - 195
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma Kathryn E. BeckermannAmita PatnaikBrian I. Rini Research 19 February 2024 Pages: 179 - 184
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer Lele ChangXuemei ZhangQingwei Li Research Open access 17 February 2024 Pages: 161 - 170
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study Miaomiao GouYong ZhangGuanghai Dai Research Open access 12 February 2024 Pages: 171 - 178
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial Andrew J. ArmstrongRavit GevaJudy S. Wang Research Open access 07 February 2024 Pages: 145 - 159
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer Naoyuki NogamiTakaaki TokitoMakoto Nishio Research Open access 01 February 2024 Pages: 136 - 144
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort Oluwadunni E. EmilojuJun YinBrian A. Costello Research 25 January 2024 Pages: 127 - 135
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis Meng-Ting LiYang HeJi-Sheng Chen Research 23 January 2024 Pages: 116 - 126
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function Jingying YueShuai ShaoMarie M Zhu Research 10 January 2024 Pages: 106 - 115
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells Mahtab AfsharzadehJaleh VarshosazFarshid Hasanzadeh Research 21 December 2023 Pages: 89 - 105
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects Hyun Chul KimEunsol YangKyung-Sang Yu Research Open access 15 December 2023 Pages: 80 - 88
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage Yue WangXingyu LinGuan Wang Research 12 December 2023 Pages: 70 - 79
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma Yanfang JiangXintong HuPingwei Zhao Research 10 December 2023 Pages: 60 - 69
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis Haibo LeiWei SunChunjiang Wang Research 08 December 2023 Pages: 53 - 59
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I- Daiki TsujiShigeru NakagakiMasaya Watanabe Research 06 December 2023 Pages: 44 - 52
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma Jasmine C. HuynhMay ChoEdward J. Kim Research Open access 01 December 2023 Pages: 35 - 43
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study Changkun ZhangXia YouDong Wang Research 17 November 2023 Pages: 24 - 34
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification Guoliang YaoJianyong YuanJingbo Chen Review 16 November 2023 Pages: 1 - 13
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide Kelsey A. FletcherMai H. AlkurashiAndrew J. Lindsay Research 14 November 2023 Pages: 14 - 23
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines Julia SchnoellCarmen SparrBernhard J. Jank Research Open access 07 November 2023 Pages: 842 - 850
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer Lan XuManyi XuZhengbo Song Research 30 October 2023 Pages: 816 - 824
Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis Chunjiang WangWei SunWeijin Fang Research 28 October 2023 Pages: 834 - 841
Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial Ting DengLe ZhangYi Ba Research Open access 27 October 2023 Pages: 808 - 815
Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells Khaled SalehMai Al SakhenBernhard Biersack Research 23 October 2023 Pages: 791 - 801
Gastrointestinal signet ring cell malignancy: current advancement and future prospects Weiping HongQingjun HuDa Wang Review 21 October 2023 Pages: 861 - 869
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts. Yoshitaka HonmaMasafumi IkedaJunji Furuse Brief Report 19 October 2023 Pages: 777 - 786
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial Yuan WuXuefeng ZhouBo Shen Research Open access 14 October 2023 Pages: 825 - 833
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation Yujie CuiJinlong LiangHongzhen Zhang Case Report 13 October 2023 Pages: 787 - 790
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States Andrea Wang-GillamWilliam SchelmanHeather Yeckes-Rodin Research Open access 05 October 2023 Pages: 851 - 860
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid Miao LiuMaoye YuanChunjiang Wang Research 29 September 2023 Pages: 802 - 807
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma Kenta YamaokaKei IrieNobuyuki Muroi Research Open access 18 September 2023 Pages: 761 - 767
